Arvinas (ARVN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 24, 2026, with voting available online until June 23, 2026.
Shareholders are encouraged to review proxy materials online or request copies before voting.
Voting matters and shareholder proposals
Election of two Class II directors: Leslie V. Norwalk, Esq. and Randy Teel, Ph.D., both recommended by the board.
Advisory vote to approve compensation of named executive officers.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.
Proxies may vote on other business arising at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends both director nominees for election to Class II positions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Arvinas
- Shareholders will vote on directors, executive pay, and auditor ratification, with strong governance and ESG focus.ARVN
Proxy filing29 Apr 2026 - Improved financials and pipeline progress set stage for key 2026 milestones and FDA review.ARVN
Q4 20259 Apr 2026 - Phase I pipeline advances, vepdegestrant nears FDA decision, and key data readouts expected in 2024.ARVN
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Multiple phase I programs advance, with key data for LRRK2 and KRAS G12D degraders expected in 2024.ARVN
Leerink Global Healthcare Conference 20269 Mar 2026 - Multiple phase I programs advance with key data and commercialization milestones ahead.ARVN
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Vepdegestrant shows strong clinical promise, with pivotal data and multiple launches expected by 2030.ARVN
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Vepdegestrant and CDK4/6 combos show strong efficacy, guiding future trial and regulatory strategies.ARVN
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Pivotal breast cancer data for vepdegestrant expected late 2024, with multiple launches planned.ARVN
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Phase III vepdegestrant data expected late 2024/early 2025, with broad pipeline progress.ARVN
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026